{"component": "definition", "props": {"groups": [{"samples": [{"hash": "kcdpiMQVJ1e", "uri": "https://www.sec.gov/Archives/edgar/data/729922/000095012396000975/1.txt", "label": "License Agreement (Oncogene Science Inc)", "score": 9.0, "published": false}, {"hash": "93GaBX1WP6B", "uri": "https://www.sec.gov/Archives/edgar/data/729922/000095012396000643/4.txt", "label": "Collaborative Research Agreement (Oncogene Science Inc)", "score": 9.0, "published": false}, {"hash": "4a6113YfVCC", "uri": "https://www.sec.gov/Archives/edgar/data/729922/000095012396000643/3.txt", "label": "Collaborative Research Agreement (Oncogene Science Inc)", "score": 9.0, "published": false}], "snippet": "means a twelve-month period terminating on each anniversary of the Effective Date.", "snippet_links": [{"key": "the-effective-date", "type": "clause", "offset": [63, 81]}], "size": 7, "hash": "8036e5528ade28a9d7becd589b85b3d0", "id": 1}, {"samples": [{"hash": "41FEdX18Jcb", "uri": "/contracts/41FEdX18Jcb#commitment-year", "label": "Chemistry Products and Services Agreement (Discovery Partners International Inc)", "score": 21.0, "published": true}, {"hash": "bIVzs7PAceS", "uri": "https://investors.infi.com/static-files/a8d0edbc-511f-4d4b-a013-9b8ddb8799b2", "label": "investors.infi.com", "score": 7.9650921822, "published": false}, {"hash": "28JMuwNCznR", "uri": "https://investors.infi.com/static-files/fd410e56-7e59-49a1-9939-fa61f8c112f1", "label": "investors.infi.com", "score": 6.9151268005, "published": false}], "snippet": "means a twelve (12) month period commencing on the Effective Date and each anniversary thereafter.", "snippet_links": [{"key": "commencing-on-the-effective-date", "type": "clause", "offset": [33, 65]}], "size": 7, "hash": "6e084ace514add364349a5279ff0fad2", "id": 2}, {"samples": [{"hash": "4JnHGlzBxOA", "uri": "/contracts/4JnHGlzBxOA#commitment-year", "label": "Protocol Development and Compound Production Agreement (Discovery Partners International Inc)", "score": 18.0, "published": true}, {"hash": "5SwT9JxlH8C", "uri": "https://investors.infi.com/static-files/b7fe45bb-2a99-4267-a96c-108206de4f7f", "label": "investors.infi.com", "score": 7.9650921822, "published": false}], "snippet": "means a twelve-month period commencing on the Effective Date and each anniversary thereafter.", "snippet_links": [{"key": "commencing-on-the-effective-date", "type": "clause", "offset": [28, 60]}], "size": 2, "hash": "c72b0b0cb50858928aed0c294f4ffdcc", "id": 3}, {"samples": [{"hash": "jC5VbZtoSx8", "uri": "/contracts/jC5VbZtoSx8#commitment-year", "label": "Collaborative Research Agreement (Isis Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "hqGpwLGVat7", "uri": "https://ir.ionispharma.com/static-files/59c3a58d-3bc5-43dc-adf6-a79e1b75c6c8", "label": "ir.ionispharma.com", "score": 9.965092659, "published": false}], "snippet": "means a twelve-month period commencing on the Effective Date and each anniversary of the Effective Date during the Contract Period.", "snippet_links": [{"key": "commencing-on-the-effective-date", "type": "clause", "offset": [28, 60]}, {"key": "during-the-contract-period", "type": "clause", "offset": [104, 130]}], "size": 2, "hash": "a7ba0dad3fdbf03cb7247d5a95c4b1ed", "id": 4}, {"samples": [{"hash": "9QMrBN6jjxB", "uri": "/contracts/9QMrBN6jjxB#commitment-year", "label": "Collaborative Research, Services and License Agreement (Nitromed Inc)", "score": 21.0, "published": true}, {"hash": "7kTyHZlaUvC", "uri": "/contracts/7kTyHZlaUvC#commitment-year", "label": "Collaborative Research, Services and License Agreement (Archemix Corp.)", "score": 21.0, "published": true}], "snippet": "means each one-year period following the Effective Date.", "snippet_links": [{"key": "year-period", "type": "definition", "offset": [15, 26]}, {"key": "following-the-effective-date", "type": "clause", "offset": [27, 55]}], "size": 2, "hash": "0c1176d7901e6bf7994221eb9f7c539b", "id": 5}, {"samples": [{"hash": "d7Q6rZC1lxK", "uri": "/contracts/d7Q6rZC1lxK#commitment-year", "label": "Collaborative Research, Development and Commercialization Agreement (Oncogene Science Inc)", "score": 18.0, "published": true}], "snippet": "means each calendar year during the term of this Agreement and, in respect of the First Commitment Year, the period commencing on the Effective Date and terminating on December 31, 1997.", "snippet_links": [{"key": "each-calendar-year", "type": "definition", "offset": [6, 24]}, {"key": "during-the-term-of-this-agreement", "type": "clause", "offset": [25, 58]}, {"key": "in-respect-of", "type": "clause", "offset": [64, 77]}, {"key": "first-commitment", "type": "definition", "offset": [82, 98]}, {"key": "the-period", "type": "clause", "offset": [105, 115]}, {"key": "commencing-on-the-effective-date", "type": "clause", "offset": [116, 148]}, {"key": "on-december", "type": "clause", "offset": [165, 176]}], "size": 2, "hash": "5146d8b64bf6687420dfb000f5b9dac4", "id": 6}, {"samples": [{"hash": "e0ihiEsXN2N", "uri": "/contracts/e0ihiEsXN2N#commitment-year", "label": "Collaborative Research Agreement (Gensia Inc)", "score": 18.0, "published": true}], "snippet": "means a twelve-month period commencing on each anniversary of the Effective Date. 1.7 \"AREA\" means research or development with respect to [CONFIDENTIAL TREATMENT REQUESTED] for the treatment of pain in human beings and animals, as further defined in the Annual Research Plan. 1.8 \"TECHNOLOGY\" means and includes all materials, technology, technical information, know-how, expertise and trade secrets within the Area. 1.9 \"GENSIA TECHNOLOGY means Technology that is or was: (a) developed by employees of or consultants to Gensia alone or jointly with third parties prior to the Effective Date or since that date in the course of activities not described in an Annual Research Plan; or; (b) acquired by purchase, license, assignment or other means from third parties by Gensia prior to the Effective Date that would not otherwise be part of Joint Technology; 1.10 \"JOINT TECHNOLOGY\" means Technology that is or was: (a) developed by employees of or consultants to Pfizer or Gensia solely or jointly with each other during the Contract Period; or (b) acquired by purchase, license, assignment or other means from third parties by Gensia or Pfizer during the Contract Period. 4 1.11 \"PFIZER TECHNOLOGY\" means Technology that is or was: (a) developed by employees of or consultants to Pfizer alone or jointly with third parties prior to the Effective Date or since that date in the course of activities not described in an Annual Research Plan; or (b) acquired by purchase, license, assignment or to other means from third parties by Pfizer prior to the Effective Date that would not be otherwise part of Joint Technology. 1.12 \"GENSIA CONFIDENTIAL INFORMATION\" means all information about any element of the Gensia or Joint Technology which is disclosed by Gensia to Pfizer and designated \"Confidential\" in writing by Gensia at the time of disclosure to Pfizer to the extent that such information as of the date of disclosure to Pfizer is not (i) demonstrably known to Pfizer other than by virtue of a prior confidential disclosure to Pfizer by Gensia; or (ii) disclosed in published literature, or otherwise generally known to the public through no fault or 5 omission of Pfizer; or (iii) obtained from a third party free from any obligation of confidentiality to Gensia. 1.13 \"PFIZER CONFIDENTIAL INFORMATION'' means all information about any element of Pfizer or Joint Technology which is disclosed by Pfizer to Gensia and designated \"Confidential\" in writing by Pfizer at the time of disclosure to Gensia to the extent that such information as of the date of disclosure to Gensia is not (i) demonstrably known to Gensia other than by virtue of a prior confidential disclosure to Gensia by Pfizer; or (ii) disclosed in published literature, or otherwise generally known to the public through no fault or omission of Gensia; or (iii) obtained from a third party free from any obligation of confidentiality to Pfizer. 1.14 \"VALID CLAIM\" means a claim within Patent Rights so long as such claim shall not have been disclaimed by either Pfizer or Gensia or both, as the case may be, or shall not have been held invalid in a final decision rendered by a tribunal of competent jurisdiction from which no appeal has been or can be taken. 1.15 \"PATENT RIGHTS\" shall mean:", "snippet_links": [{"key": "commencing-on", "type": "clause", "offset": [28, 41]}, {"key": "research-or-development", "type": "definition", "offset": [99, 122]}, {"key": "with-respect-to", "type": "clause", "offset": [123, 138]}, {"key": "confidential-treatment-requested", "type": "definition", "offset": [140, 172]}, {"key": "treatment-of-pain", "type": "definition", "offset": [182, 199]}, {"key": "further-defined", "type": "clause", "offset": [232, 247]}, {"key": "annual-research-plan", "type": "definition", "offset": [255, 275]}, {"key": "technical-information", "type": "definition", "offset": [340, 361]}, {"key": "trade-secrets", "type": "clause", "offset": [387, 400]}, {"key": "the-area", "type": "clause", "offset": [408, 416]}, {"key": "employees-of", "type": "clause", "offset": [491, 503]}, {"key": "with-third-parties", "type": "clause", "offset": [546, 564]}, {"key": "prior-to-the-effective-date", "type": "clause", "offset": [565, 592]}, {"key": "of-activities", "type": "clause", "offset": [626, 639]}, {"key": "an-annual", "type": "clause", "offset": [657, 666]}, {"key": "assignment-or", "type": "clause", "offset": [721, 734]}, {"key": "from-third-parties", "type": "clause", "offset": [747, 765]}, {"key": "joint-technology", "type": "clause", "offset": [840, 856]}, {"key": "to-pfizer", "type": "clause", "offset": [960, 969]}, {"key": "during-the-contract-period", "type": "clause", "offset": [1014, 1040]}, {"key": "pfizer-technology", "type": "definition", "offset": [1181, 1198]}, {"key": "by-pfizer", "type": "clause", "offset": [1527, 1536]}, {"key": "all-information", "type": "clause", "offset": [1664, 1679]}, {"key": "in-writing", "type": "definition", "offset": [1801, 1811]}, {"key": "at-the-time", "type": "clause", "offset": [1822, 1833]}, {"key": "to-the-extent", "type": "clause", "offset": [1858, 1871]}, {"key": "such-information", "type": "definition", "offset": [1877, 1893]}, {"key": "date-of", "type": "clause", "offset": [1904, 1911]}, {"key": "confidential-disclosure", "type": "definition", "offset": [2005, 2028]}, {"key": "to-the-public", "type": "definition", "offset": [2122, 2135]}, {"key": "no-fault", "type": "definition", "offset": [2144, 2152]}, {"key": "a-third-party", "type": "clause", "offset": [2201, 2214]}, {"key": "obligation-of-confidentiality", "type": "clause", "offset": [2229, 2258]}, {"key": "pfizer-confidential-information", "type": "definition", "offset": [2276, 2307]}, {"key": "valid-claim", "type": "clause", "offset": [2922, 2933]}, {"key": "patent-rights", "type": "definition", "offset": [2956, 2969]}, {"key": "the-case", "type": "definition", "offset": [3062, 3070]}, {"key": "final-decision", "type": "clause", "offset": [3120, 3134]}, {"key": "competent-jurisdiction", "type": "clause", "offset": [3161, 3183]}, {"key": "no-appeal", "type": "clause", "offset": [3195, 3204]}], "size": 1, "hash": "f8e755b52d36b371573b7ada88d64f6e", "id": 7}, {"samples": [{"hash": "4TkYQqTpMl3", "uri": "/contracts/4TkYQqTpMl3#commitment-year", "label": "Co Promotion Agreement (Allergan Inc)", "score": 18.0, "published": true}], "snippet": "means, for the first Commitment Year, the period beginning on the Effective Date and ending on December 31, 2006, and for each Commitment Year thereafter, each successive period beginning on January 1 and ending twelve (12) consecutive calendar months later on December 31; provided, however, that the last Commitment Year may be for a term of less than twelve (12) months until the end of the Commitment Term.", "snippet_links": [{"key": "first-commitment", "type": "definition", "offset": [15, 31]}, {"key": "beginning-on-the-effective-date", "type": "clause", "offset": [49, 80]}, {"key": "on-december", "type": "clause", "offset": [92, 103]}, {"key": "successive-period", "type": "definition", "offset": [160, 177]}, {"key": "calendar-months", "type": "clause", "offset": [236, 251]}, {"key": "term-of", "type": "clause", "offset": [336, 343]}, {"key": "commitment-term", "type": "definition", "offset": [394, 409]}], "size": 1, "hash": "0c933a122057ab8f1dbabbee8cfba71a", "id": 8}, {"samples": [{"hash": "1PytVhsl32i", "uri": "/contracts/1PytVhsl32i#commitment-year", "label": "Resale and Marketing Agreement (Covad Communications Group Inc)", "score": 18.0, "published": true}], "snippet": "means the twelve-month period from October 1 to September 30, commencing on October 1, 2000 and continuing through the remainder of the Commitment Period.", "snippet_links": [{"key": "period-from", "type": "definition", "offset": [23, 34]}, {"key": "october-1", "type": "definition", "offset": [35, 44]}, {"key": "commencing-on", "type": "clause", "offset": [62, 75]}, {"key": "commitment-period", "type": "clause", "offset": [136, 153]}], "size": 1, "hash": "42eff2c2efb70ee82922ed29e0cc403d", "id": 9}, {"samples": [{"hash": "li7ZmYW83Gr", "uri": "/contracts/li7ZmYW83Gr#commitment-year", "label": "Co Promotion Agreement (Cv Therapeutics Inc)", "score": 21.0, "published": true}], "snippet": "means a 12 month period beginning on the Commencement Date and on subsequent anniversaries of the Commencement Date; provided, however, that the last Commitment Year may be for a term of less than 12 months until the end of the Commitment Term.", "snippet_links": [{"key": "beginning-on-the-commencement-date", "type": "clause", "offset": [24, 58]}, {"key": "term-of", "type": "clause", "offset": [179, 186]}, {"key": "commitment-term", "type": "definition", "offset": [228, 243]}], "size": 1, "hash": "edbd3b3c8e826870eae240e21c113362", "id": 10}], "next_curs": "ClwSVmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjgLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIYY29tbWl0bWVudC15ZWFyIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"title": "Commitment Year", "snippet": "means a twelve-month period terminating on each anniversary of the Effective Date.", "size": 29, "id": "commitment-year", "examples": ["The Annual Research Plan and the Annual Sponsored Research Plan for each <strong>Commitment Year</strong> shall be appended to and made part of this Agreement.", "Each new Annual Research Plan for each succeeding <strong>Commitment Year</strong> shall be appended to Exhibit B and made part of this Agreement.", "If, Pfizer does not audit the records of a <strong>Commitment Year</strong> within [***] years after the end of that year, Pfizer will be deemed to have accepted the accuracy of the records.", "The Annual Research Plan for the first <strong>Commitment Year</strong> is described in the attached Exhibit B.", "If during the *** Firm <strong>Commitment Year</strong>, PARTNER has not performed the required Work Program in such Firm <strong>Commitment year</strong>, PARTNER may propose a written request to PERTAMINA EP no later than *** before the end of such Firm <strong>Commitment year</strong> to carry forward the Work Program which are not performed to the next Firm <strong>Commitment year</strong>.", "For each <strong>Commitment Year</strong> after the first <strong>Commitment Year</strong>, an Annual Research Plan shall be prepared by the Research Committee for submission to, and approval by, Wyeth and OSI no later than sixty (60) days before the end of the prior <strong>Commitment Year</strong>.", "The amount of Funding Payments for each quarter shall be the number of person months expended in the Research Program in the quarter multiplied by one-twelfth of the Cost/person year for the applicable <strong>Commitment Year</strong>.", "Each new Annual Research Plan for each succeeding <strong>Commitment Year</strong> shall be appended to Exhibit A and made part of this Agreement.", "The Annual Research Plan for the first <strong>Commitment Year</strong> is described in the attached Exhibit A.", "Wyeth shall have the option to extend the Annual Research Plan beyond the second <strong>Commitment Year</strong>, which extension shall be on the basis of mutual agreement of the parties."], "related": [["available-unused-commitment", "Available Unused Commitment", "Available Unused Commitment"], ["unused-revolving-commitment", "Unused Revolving Commitment", "Unused Revolving Commitment"], ["incremental-term-commitment", "Incremental Term Commitment", "Incremental Term Commitment"], ["available-commitment", "Available Commitment", "Available Commitment"], ["total-incremental-term-loan-commitment", "Total Incremental Term Loan Commitment", "Total Incremental Term Loan Commitment"]], "related_snippets": [], "updated": "2025-08-01T04:31:04+00:00"}, "json": true, "cursor": ""}}